OXB is a specialist advanced therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining proprietary drug candidates. OXB will also receive royalties on commercial therapies developed with its LentiVector® platform. The first such therapy, also the first CAR-T therapy to ever be approved, was licensed by the FDA on 30P th P August 2017: tisagenlecleucel (KymriahP TMP) is manufactured by Novartis using lentivirus vector supplied by OXB. OXB will be the first UK company to manufacture viral vector for commercial production of a licensed gene-based medicine.
